

**Prototype for Adult Medical Facility Orders During a Radiation Event**  
Version 7/16/2008

**Cautions**

- Orders must be customized for each event and patient!
- Specific drugs are suggested for function only, and patients may not need any/every category of drug listed. Consult the notes at the end of this document.
- This Adult Orders Prototype lists only FDA-approved medications as radioisotope countermeasures for internal contamination; see page 9-10. These drugs are currently in the [Strategic National Stockpile](#). Prescribers should consult the FDA drug label for complete information.
- All dosages in this prototype are based on a 70 kg adult with normal renal and hepatic function. Appropriate dosage adjustments should be made based on age, weight, drug-drug interactions, nutritional status, renal and hepatic function. Pediatric doses are not referenced, except for Potassium Iodide.
- This Adult Orders Prototype does **not** address threshold levels of internal contamination that would trigger initiation, continuation, or discontinuation of decorporation treatment. See [REMM Countermeasures Caution and Comment](#) information that discusses this issue.
- After a mass casualty event, practitioners may encounter counterfeit drugs. This [FDA website](#) will provide information on avoiding and detecting counterfeit drugs and assist reporting of suspected counterfeit medications.
- See "Notes" at end of order list for additional information.

## 1. Administrative information

Name: \_\_\_\_\_

Unique Identifier: \_\_\_\_\_

Address: \_\_\_\_\_

Phone: \_\_\_\_\_

Spoken language: \_\_\_\_\_

### Admit to:

\_\_\_ Hospital ward \_\_\_\_\_ \_\_\_ Area \_\_\_\_\_

\_\_\_ Team: \_\_\_\_\_ \_\_\_ ICU \_\_\_\_\_

\_\_\_ Physician: \_\_\_\_\_ \_\_\_ Other \_\_\_\_\_

Next of kin contact information: \_\_\_\_\_

Special needs: \_\_\_\_\_

## 2. Diagnoses: Radiation, Other

### \_\_\_ Radiation contamination: description

- See REMM [Body Chart](#) (page 14) to record whole body radiation survey.
  - \_\_\_ External contamination with Isotope (Specify) \_\_\_\_\_
  - \_\_\_ Internal contamination with Isotope (Specify) \_\_\_\_\_
  - \_\_\_ Contamination suspected, Isotope uncertain

### \_\_\_ Radiation Exposure / Acute Radiation Syndrome (ARS)

- See REMM information on [Dose Reconstruction](#).
  - \_\_\_ Date of exposure \_\_\_\_\_
  - \_\_\_ Time of exposure \_\_\_\_\_
  - \_\_\_ Location of patient at time of exposure \_\_\_\_\_
  - \_\_\_ Estimated whole body/partial body dose, specify \_\_\_\_\_ (dose)
  - \_\_\_ Dose unknown

### \_\_\_ Other potential complicating factors

- \_\_\_ Combined injuries? e.g. burn, blast, fracture, other  
Specify: \_\_\_\_\_
- \_\_\_ Mass casualty incident

**Prototype for Adult Medical Facility Orders During a Radiation Event**  
Version 7/16/2008

**\_\_\_ Specific populations potentially requiring more customized management**

See REMM [Specific Populations](#) page

- Young age (e.g. children < 12-16 y)     Older age (e.g., those > 65 y)  
 Pregnant/Possibly pregnant             Immunosuppressed

**\_\_\_ History of prior significant chronic disease(s) or conditions.**

Specify each, including meds or special needs required for each:

---

---

---

---

---

**Urgent Consultations as indicted:**

- |  |   |
|--|---|
| <input type="checkbox"/> Hematopoietic Stem Cell Transplantation | <input type="checkbox"/> Radiation Oncology   |
| <input type="checkbox"/> Hematology / Oncology                   | <input type="checkbox"/> Transfusion Medicine |
| <input type="checkbox"/> Mental Health / Psychiatry              | <input type="checkbox"/> Endocrinology        |
| <input type="checkbox"/> Ophthalmology                           | <input type="checkbox"/> Radiation Oncology   |
| <input type="checkbox"/> Dermatology / Plastic Surgery           | <input type="checkbox"/> Gastroenterology     |
| <input type="checkbox"/> Radiation Safety                        | <input type="checkbox"/> Burn Therapy         |

**3. Condition:**

- Good     Fair     Stable     Guarded     Critical

**4. Vital Signs:**

- q 2 hours X 4  
 q 4 hours X 4  
 Ward routine

Notify physician for:

- Temperature > 38.5 °C  
 SBP > 180, <100  
 DBP > 100 < 50  
 HR >100 <50  
 RR >30 <8  
 O<sub>2</sub> saturation < 92%

**Prototype for Adult Medical Facility Orders During a Radiation Event**

Version 7/16/2008

**5. Special orders for patients with radiation contamination:**

Radiation precautions

**Use radiation precautions unless patient is known with certainty to have had only external exposure to radiation.**

- Universal precautions with gown, mask, cap, boots, and gloves
- Use medical facility procedures for discarding biological/physical/radioactive waste, including linens/towels/trash/personal protective equipment.
- Contact Radiation Safety Officer for additional instructions.  
phone: \_\_\_\_\_ page: \_\_\_\_\_
- Place radiation safety sign on door if patient has internal or external radioactive contamination.
- Notify pregnant staff that entry to room is prohibited if patient is/may be contaminated.
- Everyone entering room/area of contaminated patient must wear personal radiation dosimeter.

**6. Allergies:**

No Known Drug Allergies (NKDA)

Allergies (drugs, foods)

If yes, specify: \_\_\_\_\_

**7. Activity:**

Bed rest

Bathroom privileges

Out of bed every \_\_\_\_\_ hrs.

Ambulate as tolerated

**8. Diet:**

Regular Diet     Liquids (full, clear)     NPO

Advance as tolerated

Other \_\_\_\_\_

Special dietary needs/requests \_\_\_\_\_

**9. Height, weight, age:**

Height: \_\_\_\_\_ feet \_\_\_\_\_ inches  
          \_\_\_\_\_ cm

Weight: \_\_\_\_\_ lbs \_\_\_\_\_ oz  
          \_\_\_\_\_ kg

Age: \_\_\_\_\_ years

Repeat body weight:

q \_\_\_\_\_ hours

q \_\_\_\_\_ days

**10. Peripheral IV management:**

IV Fluids: \_\_\_\_\_ @ \_\_\_\_\_ cc/hr, with additive \_\_\_\_\_

IV Fluids: \_\_\_\_\_ @ \_\_\_\_\_ cc/hr, with additive \_\_\_\_\_

**11.  Foley catheter management**

**Use radiation precautions for urine and feces for patients with radiation contamination.**

**12.  Monitor I / O**

Frequency \_\_\_\_\_

**Use radiation precautions for urine and feces for patients with radiation contamination.**

**13. Deep Venous Thrombosis (DVT) prophylaxis<sup>1</sup>:**

TED hose to Bilateral Lower-Extremities

Sequential Compression Devices (SCD)

Anticoagulation regimen \_\_\_\_\_

Other

The potential benefit of anticoagulation (e.g. **heparin**<sup>1,2</sup>) should be balanced against the risk of excessive bleeding in patients with severe thrombocytopenia or significant gastrointestinal toxicity.

**14. Respiratory Therapy:** (Radiation precautions needed if patient is contaminated.)

Room air     Chest tube care (Specify) \_\_\_\_\_

Titrate oxygen supplementation for Oxygen saturation > \_\_\_\_\_%

Nebulizer treatment (Specify) \_\_\_\_\_

**15. Wound care<sup>1</sup>: (see also item 22: burn therapy)**

Decontaminate external wounds if there is external contamination.  
See REMM [contaminated wound](#) care recommendations.

Sterile dressing to wounds daily

Monitor waste: Use medical facility procedures for discarding biological/radioactive/physical waste and linens/towels/trash/personal protective equipment. Radiation precautions needed if patient is contaminated.

**Silvadene ([Silver Sulfadiazine](#))**<sup>2</sup> cream topically to burns

**Prototype for Adult Medical Facility Orders During a Radiation Event**

Version 7/16/2008

\_\_\_ Other wound management per Burn team/Dermatology/Plastic Surgery:  
Pager \_\_\_\_\_ Phone \_\_\_\_\_

**16. Orthopedic care:**

\_\_\_ Splint/brace/cast

\_\_\_ Other orthopedic management procedure per orthopedics:  
Pager \_\_\_\_\_ Phone \_\_\_\_\_

**17. Admission labs / imaging studies / other:**

\_\_\_ CBC w/differential

\_\_\_ Comprehensive Metabolic Panel (CMP) / Chem 14

\_\_\_ Cardiac enzymes

\_\_\_ PT / PTT

\_\_\_ Urinalysis

\_\_\_ Urine culture

\_\_\_ Blood culture x 2

\_\_\_ Urine HCG

\_\_\_ Serum HCG

\_\_\_ Thyroid Function Tests (Specify) \_\_\_\_\_

\_\_\_ Serologies:

Herpes Simplex Virus type 1 (HSV-1)

Herpes Simplex Virus type 2 (HSV-2)

Cytomegalovirus (CMV)

Varicella-zoster virus (VZV)

\_\_\_ Electrocardiogram

\_\_\_ Chest x-ray \_\_\_\_\_ PA/Lat \_\_\_\_\_ Portable

\_\_\_ Other imaging studies Specify: \_\_\_\_\_

**18. Standing labs / studies:**

\_\_\_ CBC w/diff q \_\_\_\_\_ hours, x \_\_\_\_\_ days,  
Followed by q \_\_\_\_\_ hours until further orders

\_\_\_ Comprehensive Metabolic Panel (CMP) / Chem 14  
Followed by q \_\_\_\_\_ hours, x \_\_\_\_\_ days  
Followed by q \_\_\_\_\_ days

**19. Electrocardiogram**

\_\_\_ STAT Electrocardiogram for chest pain, notify physician

**20. Biodosimetry/Bioassay tests:** See REMM's [Explaining Biodosimetry](#).

**For biodosimetry:** See REMM for more on the [Dicentric chromosome assay](#).

\_\_\_ Draw extra green top tube on: date \_\_\_\_\_ time \_\_\_\_\_  
Send this tube **ON ICE** for outside lab study  
To the Attention of: \_\_\_\_\_  
Name of Lab: \_\_\_\_\_  
Address of Lab: \_\_\_\_\_  
See REMM for location of [laboratories that perform this test](#).

**For Bioassay: tests evaluating/managing internal decontamination:**

\_\_\_ Spot urine for \_\_\_\_\_ name of radioactive isotope  
\_\_\_ 24-hour urine for \_\_\_\_\_ name of radioactive isotope  
\_\_\_ Spot fecal specimen for \_\_\_\_\_ name of radioactive isotope  
\_\_\_ 24-hour fecal specimen for \_\_\_\_\_ name of radioactive isotope  
Send specimen to: \_\_\_\_\_  
Special requirements for containment, labeling, and shipping of specimen:  
\_\_\_\_\_

Note: Consult senior radiation event medical managers for name and location of specialized laboratories if your facility cannot perform these assays.

**21. \_\_\_ Type and screen**

For \_\_\_ units of packed red blood cells  
For \_\_\_ units of platelets

- **Use only leukoreduced AND irradiated products, if available, unless it is known with certainty that the patient was exposed to a low dose of radiation, e.g. less than 100 Gy.**
- **If dose is not known with certainty, leukoreduced AND irradiated blood is preferred, if available.**
- **See [REMM blood use page](#) for additional information.**

## 22. General Medications<sup>1</sup>:

### For gastric acid suppression:

\_\_\_ **Lansoprazole (Prevacid)**<sup>2</sup> 15-30 mg PO daily

### For radiation-induced nausea & vomiting:

\_\_\_ **Ondansetron (Zofran)**<sup>2</sup> 4 mg IV q 8h PRN nausea/emesis

\_\_\_ **Lorazepam (Ativan)**<sup>2</sup> 0.5 mg – 1 mg PO q 6-8h PRN  
anxiety/insomnia/breakthrough nausea

- See [American Society of Clinical Oncology 2006 Anti-emetic Guidelines](#)<sup>3</sup>
- See NEJM June 5, 2008 article: [chemotherapy induced nausea and vomiting](#)<sup>3</sup>

### For fever:

\_\_\_ **Acetaminophen (Tylenol)**<sup>2</sup> 650 mg PO q 6 – 8h PRN temperature > 38 °C

### For diarrhea:

\_\_\_ **Loperamide hydrochloride (Imodium)**<sup>2</sup>:

- Recommended initial dose is 4 mg (2 capsules) followed by 2 mg (1 capsule) after each unformed stool.
- Daily dose should not exceed 16 mg (8 capsules)

### For constipation:

\_\_\_ **Senna (Senokot)**<sup>2</sup> 2 tabs PO BID, hold for loose stools

\_\_\_ **Docusate (Colace)**<sup>2</sup> 100 mg PO BID, hold for loose stools  
FDA monograph: 50 to 360 mg QD or divided BID for adults

### For rash:

\_\_\_ Topical sterile dressing

\_\_\_ **Diphenhydramine hydrochloride (Benadryl)**<sup>2</sup> 25-50 mg PO q 4-6 hours  
for pruritis, not to exceed 300 mg/24 hours

### For pain:

\_\_\_ **Morphine sulphate**<sup>2</sup> \_\_\_\_ mg \_\_\_\_ route \_\_\_\_ frequency

### For skin burns: (see also item 15: wound care)

Burn topical regimen \_\_\_\_\_

Replace body fluid \_\_\_\_\_

**Prototype for Adult Medical Facility Orders During a Radiation Event**  
 Version 7/16/2008

Other burn therapy \_\_\_\_\_

**For oral mucositis:**

Mouth care regimen \_\_\_\_\_

**23. For radioisotope decorporation or blocking:**

- Note: Only FDA approved radiation countermeasures are listed in table below.
- See [REMM Countermeasures Table](#) for longer list of countermeasures which have been recommended by some experts but are not FDA approved as radiation countermeasures.

Medication	Administered for which Isotopes	Route of Administration & Dosage for adults	Duration
<b>Ca-DTPA<sup>2,4</sup></b> <b>Zn-DTPA<sup>2,4</sup></b>  <a href="#">See REMM's DTPA information.</a>  <a href="#">See FDA's Zn-DTPA drug label.</a>  <a href="#">See FDA's Ca-DTPA drug label.</a>	Plutonium-239 <sup>2</sup> Americium-241 <sup>2</sup> Curium-244 <sup>2</sup> Californium-252 <sup>3</sup> Thorium-232 <sup>3</sup> Yttrium-90 <sup>3</sup>	<b>IV<sup>2</sup>: (for Zn or Ca)</b> 1 g in 250 mL NS or 5% glucose, given in 1-2 h, or bolus over 3-4 min; given once daily as a single infusion  <b>Nebulized inhalation<sup>2</sup>:</b> 1 g in 1:1 dilution with water or NS over 15-20 min	Up to 5 days

**Prototype for Adult Medical Facility Orders During a Radiation Event**

Version 7/16/2008

<p><b>Potassium iodide<sup>2</sup></b></p> <p><a href="#">See REMM's KI summary information.</a></p> <p><a href="#">See FDA's KI information.</a></p>	<p>Iodine-131</p>	<p><b>PO:</b></p> <p><b>Adults &gt;40 years of age</b> with thyroid exposure ≥ 500 cGy: 130 mg/d</p> <p><b>Adults 18-40 years of age</b> with thyroid exposure ≥ 10 cGy: 130 mg/d</p> <p><b>Pregnant or lactating women</b> with thyroid exposure ≥ 5 cGy: 130 mg/d</p> <p><b>Children and adolescents 3-18</b> with thyroid exposure ≥ 5 cGy: 65 mg/d</p> <p>Adolescents approaching adult size (70 kg) should receive full adult dose of 130 mg/d.</p> <p><b>Infants 1 month to 3 years</b> with thyroid exposure ≥ 5 cGy: 32.5 mg/d</p> <p><b>Neonates from birth to 1 month</b> with thyroid exposure ≥ 5 cGy: 16 mg/d</p>	<ul style="list-style-type: none"> <li>• In some incidents only a single dose of KI is required.</li> <li>• Incident Managers may recommend additional daily doses if radioactive iodine ingestion (or inhalation) is a continuing threat.</li> <li>• In some incidents, a course of 7-14 days may be recommended.</li> </ul>
<p><b>Prussian blue<sup>2</sup></b></p> <p><a href="#">See REMM's Prussian Blue information.</a></p> <p><a href="#">See FDA's Prussian Blue drug label.</a></p>	<p>Cesium-137, Thallium-201</p>	<p><b>PO:</b> 1 - 3 g TID with 100-200 mL water, up to 10 g/day</p>	<p>≥3 weeks, titrated by urine and/or fecal radionuclide bioassay and whole-body counting</p>

**Prototype for Adult Medical Facility Orders During a Radiation Event**  
 Version 7/16/2008

**24. Neutropenia therapy, if indicated<sup>1, 5</sup>:**

- Although the 3 drugs listed below are FDA-approved for the treatment of chemotherapy induced neutropenia, none is approved either for radiation induced neutropenia or as prophylactic treatment prior to the onset of neutropenia.
- In a mass casualty radiation event, use of these drugs would require a formal [Emergency Use Authorization](#).
- Consult drug label in links below for each drug.
- See additional REMM information on [white cell growth factors/cytokines](#).

<b>Cytokine<sup>3</sup></b>	<b>Adult dose</b>	<b>Pregnant Women<sup>6</sup></b>
G-CSF or filgrastim <sup>3</sup> ( <a href="#">Neupogen</a> )	<ul style="list-style-type: none"> <li>• Subcutaneous administration</li> <li>• 5 ug/kg/day via single daily injection</li> <li>• Continue until absolute neutrophil count &gt; 1.0 x 10<sup>9</sup> cells/L</li> </ul>	Class C <sup>6</sup> (Same as adults)
Pegylated G-CSF or pegfilgrastim <sup>3</sup> ( <a href="#">Neulasta</a> )	<ul style="list-style-type: none"> <li>• 1 subcutaneous dose, 6 mg</li> </ul>	Class C <sup>6</sup> (Same as adults)
GM-CSF or sargramostim <sup>3</sup> ( <a href="#">Leukine</a> )	<ul style="list-style-type: none"> <li>• Subcutaneous administration</li> <li>• 250 ug/m<sup>2</sup>/day</li> <li>• Continue until absolute neutrophil count &gt; 1.0 x 10<sup>9</sup> cells/L</li> </ul>	Class C <sup>6</sup> (Same as adults)

**See Practice Guidelines for myeloid growth factors**

- [National Comprehensive Cancer Network](#)
- [American Society of Clinical Oncology](#)

**Antimicrobial therapy<sup>1</sup>:**

- Use as appropriate for each patient.
- Drugs listed are examples only.

**Anti-bacterial**

\_\_\_ **Levofloxacin ([Levaquin](#))<sup>2</sup>** 500 mg PO/IV qd

**Anti-viral**

\_\_\_ **Acyclovir ([Zovirax](#))<sup>2</sup>** 400 mg PO q12h, or  
 \_\_\_ **Acyclovir ([Zovirax](#))<sup>2</sup>** 250 mg/m<sup>2</sup> IV q12h

**Anti-fungal**

\_\_\_ **Fluconazole ([Diflucan](#))<sup>2</sup>** 400 mg PO/IV daily – beginning when absolute neutrophil Count (ANC) becomes < 1000, or  
 \_\_\_ **Posaconazole ([Noxafil](#))<sup>2</sup>** 200 mg PO tid with food – beginning when absolute Neutrophil Count (ANC) becomes < 1000

**Prototype for Adult Medical Facility Orders During a Radiation Event**  
 Version 7/16/2008

**25. Fever and Neutropenia<sup>1</sup>**

- |  |                          |
|--|--------------------------|
| ___ Blood cultures x 2 sets  | ___ Urinalysis w/culture |
| ___ Sputum culture + sensitivity   | ___ Chest x-ray          |
| ___ <b>Cefepime (<a href="#">Maxipime</a>)<sup>2</sup></b> 2 gm IV q 8h (use as appropriate)                               |                          |
| ___ <b>Vancomycin (<a href="#">Vancocin</a>)<sup>2</sup></b> 1gm IV q 12h, check peak and trough level before the 4th dose |                          |

See current Neutropenia Guidelines from

- [IDSA](#) Infectious Diseases Society of America
- [ASCO](#) American Society of Clinical Oncology

**Consider using one of the following<sup>1</sup>:**

- \_\_\_ **Liposomal amphotericin B ([Ambisome](#))<sup>2</sup>** 3mg/kg/day IV over 1-4h
- \_\_\_ **Amphotericin B lipid complex ([Abelcet](#))<sup>2</sup>** 3mg/kg/day IV over 1-4h
- \_\_\_ **Voriconazole ([Vfend](#))<sup>2</sup>** 6mg/kg IV q 12h for two doses, then 4mg/kg IV q 12h
- \_\_\_ **Caspofungin ([Cancidas](#))<sup>2</sup>** 70mg IV once then 50mg IV q 24h

**NOTES**

1. Suggested drugs are listed as representatives of a functional class, and no specific medication endorsement is implied. Dosages are based on a 70 kg adult with normal baseline renal and hepatic function. Appropriate dosage adjustments should be made based on age, weight, drug-drug interactions, nutritional status, renal and hepatic function, and any other patient-specific characteristics that may apply.
2. FDA approved for this indication
3. This drug is **not** approved by the FDA for this indication. If used, this would be an "off label use", and physician discretion is strongly advised.
4. Ca-DTPA and Zn-DTPA have not been approved by FDA for treating internal contamination with californium, thorium, and yttrium. For initial treatment, Ca-DTPA is recommended, if available, within the first 24 hours after internal contamination. Zn-DTPA is preferred for maintenance after the first 24 hours, if available, due to safety concerns associated with prolonged use of Ca-DTPA.
5. When to initiate treatment with cytokines
  - Initiation of treatment should be strongly considered for victims who develop an absolute neutrophil count of  $< 0.500 \times 10^9$  cells/L and are not already receiving colony-stimulating factor.
  - Evidence from **animal studies** indicates that outcomes may be improved if colony stimulating factors are administered as soon as possible after radiation exposure, and prior to the onset of neutropenia.

**Prototype for Adult Medical Facility Orders During a Radiation Event**

Version 7/16/2008

- Although most therapy for ARS is directed at actual clinical signs and symptoms, some clinical effects of ARS can be **anticipated and potentially mitigated**, as with the use of prophylactic [white cell cytokines](#). This prophylactic use is also off label.
  - [Emergency Use Authorization](#) will be required for use of cytokines for radiation induced neutropenia in a mass casualty setting.
  - See published guidelines links in section 24.
6. For pregnant women:
- Experts in biodosimetry must be consulted.
  - Any pregnant patient with exposure to radiation should be evaluated by a health physicist and maternal-fetal specialist for an assessment of risk to the fetus.
  - Class C refers to U.S. Food and Drug Administration Pregnancy Category C, which indicates that studies have shown animal, teratogenic, or embryocidal effects, but there are no adequate controlled studies in women; or no studies are available in animals or pregnant women.

**Prototype for Adult Medical Facility Orders During a Radiation Event**  
Version 7/16/2008

**Body Chart for Recording Results of Radiation Survey**

